Senators press PBMs to clarify Azar's ‘extremely disturbing' drug pricing allegations

Elizabeth Warren
Elizabeth Warren asked nine PBMs to respond to Azar's accusations that the companies have blocked voluntary drug price reductions. (CSPAN)

Two senators have asked prominent pharmacy benefit managers to address accusations from the Trump administration’s top health official that PBMs are preventing drug manufacturers from lowering prices.

In letters to nine PBMs, including Express Scripts, CVS Health and OptumRx, Sens. Elizabeth Warren, D-Mass., and Tina Smith, D-Minn., asked the companies to explain statements made by Department of Health and Human Services Secretary Alex Azar that PBMs have blocked voluntary priced reductions by drug makers. Those accusations could prompt antitrust concerns, the senators said. 

In hearings before two separate Senate committees last month, Azar suggested PBMs were creating hurdles for pharmaceutical companies who want to lower the list price by threatening to remove the drug from their formulary. His statements came several weeks after President Donald Trump promised several companies would be issuing voluntary price reductions.

Conference

2019 Drug Pricing and Reimbursement Stakeholder Summit

Given federal and state pricing requirements arising, press releases from industry leading pharma companies, and the new Drug Transparency Act, it is important to stay ahead of news headlines and anticipated requirements in order to hit company profit targets, maintain value to patients and promote strong, multi-beneficial relationships with manufacturers, providers, payers, and all other stakeholders within the pricing landscape. This conference will provide a platform to encourage a dialogue among such stakeholders in the pricing and reimbursement space so that they can receive a current state of the union regarding regulatory changes while providing actionable insights in anticipation of the future.

"I would encourage the Senate and Congress to inquire of pharmacy benefit managers as to whether they have received suggestions or approaches from drug companies for lower list prices and what has the reaction been," he told members of the Senate Finance Committee last week. 

RELATED: Azar blames PBMs for ‘broken system’ in Senate Finance hearing dominated by immigration debate

“These are extremely disturbing allegations by Secretary Azar,” the senators wrote (PDF). “If they are true, these allegations suggest that PBMs and drug distributors are acting to maintain high list prices in order to maintain high profit margins, potentially raising antitrust concerns.”

In addition to CVS Health, Express Scripts and OptumRx, the senators sent letters to executives at CardinalHealth, McKesson, AmerisourceBergen, Medimpact Healthcare System, Prime Therapeutics and Humana.

RELATED: Elizabeth Warren to Alex Azar: Where are 'massive' voluntary drug price reductions?

If Azar’s comments are true, they “directly contradict” public statements from PBMs regarding their role in reducing drug prices, the lawmakers said. They included a list of questions requesting more detail about discussions the companies have had with drug makers, whether they “pushed back” on lower list prices, and whether they threatened to remove drugs from their formulary.

They requested answers no later than July 13.

In a statement following last week’s Senate Finance hearing on drug prices, the Pharmaceutical Care Management Association’s President and CEO Mark Merritt placed the onus on manufacturers.

“The easiest way to lower costs would be for drug companies to lower their prices,” he said.

Suggested Articles

We need our federal programs and policies to reflect the goal of improving the health of both women and men.

Two lawsuits were filed suing the Trump administration to overturn a new rule that would allow healthcare workers to deny care over religious or conscience…

Policy changes are affecting how investors view the skilled home health market and paving the way for potential strategic acquisitions.